adenine has been researched along with Granuloma, Hodgkin in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patient initiated ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) chemotherapy and presented with neutropenia and severe hypokalemia." | 3.85 | Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. ( Arcondo, F; Cordova, E; Morganti, L; Odzak, A; Rodriguez, C; Silva, M; Zylberman, M, 2017) |
| "Melatonin (Mel) has been shown to involve in many essential cell functions via modulating many signaling pathways." | 1.56 | Melatonin triggers autophagic cell death by regulating RORC in Hodgkin lymphoma. ( Du, W; Gong, R; He, M; He, X; Lei, H; Li, G; Li, X; Pang, P; Wang, Y; Yan, G; Yu, S; Yuan, Y, 2020) |
| "The established treatment algorithms for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are currently challenged by novel classes of drugs, with ibrutinib being one of the most effective." | 1.46 | Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related? ( Kalpadakis, C; Koulieris, E; Moschogiannis, M; Pangalis, GA; Rontogianni, D; Sachanas, S; Tsirkinidis, P; Yiakoumis, X, 2017) |
| "Rare cases of transformation to Hodgkin lymphoma (HL) have been reported in the literature with an estimated prevalence of 0." | 1.46 | Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia. ( Catherwood, M; Glavey, S; Leader, M; Marafioti, T; McCartney, Y; McCloy, M; Murphy, P; Quinn, J; Sargent, J; Thornton, P, 2017) |
| "In a xenograft model of Hodgkin's lymphoma, HSP90 inhibition significantly delayed tumor growth." | 1.35 | Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. ( Böll, B; Burrows, FJ; Eltaib, F; Engert, A; Hansen, HP; Lundgren, K; Reiners, KS; Simhadri, VR; Tawadros, S; von Strandmann, EP; von Tresckow, B, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Eichenauer, DA | 1 |
| Bühnen, I | 1 |
| Plütschow, A | 1 |
| Kobe, C | 1 |
| Dietlein, M | 1 |
| Wendtner, CM | 1 |
| Thorspecken, S | 1 |
| Topp, MS | 1 |
| Mauser, M | 1 |
| von Tresckow, B | 2 |
| Fuchs, M | 1 |
| Borchmann, P | 1 |
| Engert, A | 2 |
| Yan, G | 1 |
| Lei, H | 1 |
| He, M | 1 |
| Gong, R | 1 |
| Wang, Y | 1 |
| He, X | 1 |
| Li, G | 1 |
| Pang, P | 1 |
| Li, X | 1 |
| Yu, S | 1 |
| Du, W | 1 |
| Yuan, Y | 1 |
| Badar, T | 1 |
| Astle, J | 1 |
| Kakar, IK | 1 |
| Zellner, K | 1 |
| Hari, PN | 2 |
| Hamadani, M | 2 |
| Koshiishi, M | 1 |
| Odate, T | 1 |
| Nakagawa, Y | 1 |
| Suzuki, J | 1 |
| Kumagai, T | 1 |
| Kawashima, I | 1 |
| Yamamoto, T | 1 |
| Nakajima, K | 1 |
| Tanaka, M | 1 |
| Oishi, N | 1 |
| Kondo, T | 1 |
| Kirito, K | 1 |
| Gángó, A | 1 |
| Kiss, R | 1 |
| Farkas, P | 1 |
| Hanna, E | 1 |
| Demeter, J | 1 |
| Deák, B | 1 |
| Lévai, D | 1 |
| Kotmayer, L | 1 |
| Alpár, D | 1 |
| Matolcsy, A | 1 |
| Bödör, C | 1 |
| Mátrai, Z | 1 |
| Timár, B | 1 |
| Cordova, E | 1 |
| Morganti, L | 1 |
| Odzak, A | 1 |
| Arcondo, F | 1 |
| Silva, M | 1 |
| Zylberman, M | 1 |
| Rodriguez, C | 1 |
| Sachanas, S | 1 |
| Pangalis, GA | 1 |
| Moschogiannis, M | 1 |
| Yiakoumis, X | 1 |
| Koulieris, E | 1 |
| Tsirkinidis, P | 1 |
| Kalpadakis, C | 1 |
| Rontogianni, D | 1 |
| Glavey, S | 1 |
| Quinn, J | 1 |
| McCloy, M | 1 |
| Sargent, J | 1 |
| McCartney, Y | 1 |
| Catherwood, M | 1 |
| Marafioti, T | 1 |
| Leader, M | 1 |
| Murphy, P | 1 |
| Thornton, P | 1 |
| Jamroziak, K | 1 |
| Szymczyk, A | 1 |
| Hus, M | 1 |
| Wojciechowska, M | 1 |
| Knopinska-Posłuszny, W | 1 |
| Hołojda, J | 1 |
| Hałaburda, K | 1 |
| Warzocha, K | 1 |
| Iskierka-Jażdżewska, E | 1 |
| Arney, K | 1 |
| Balasubramanian, S | 1 |
| Böll, B | 1 |
| Eltaib, F | 1 |
| Reiners, KS | 1 |
| Tawadros, S | 1 |
| Simhadri, VR | 1 |
| Burrows, FJ | 1 |
| Lundgren, K | 1 |
| Hansen, HP | 1 |
| von Strandmann, EP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Dose-escalation, Pharmacokinetic and Pharmacodynamic Study of Debio 0932, a Novel Hsp90-inhibitor, Administered Orally, in Patients With Advanced Solid Tumours or Lymphoma[NCT01168752] | Phase 1 | 81 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for adenine and Granuloma, Hodgkin
| Article | Year |
|---|---|
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group.
Topics: Adenine; Hodgkin Disease; Humans; Lymphocytes; Neoplasm Recurrence, Local; Piperidines | 2022 |
11 other studies available for adenine and Granuloma, Hodgkin
| Article | Year |
|---|---|
Melatonin triggers autophagic cell death by regulating RORC in Hodgkin lymphoma.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Autophagic Cell Death; Cell Line, Tumor; Cell Survival; H | 2020 |
Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Hematopoietic Stem Cell Transplantation; | 2020 |
Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.
Topics: Adenine; Aged; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; | 2021 |
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Female; Genes, | 2022 |
Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Drug I | 2017 |
Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?
Topics: Adenine; Aged; Antineoplastic Agents; Biopsy; Cell Transformation, Neoplastic; Disease Progression; | 2017 |
Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2017 |
Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG).
Topics: Adenine; Adult; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-C | 2018 |
Solving lymphoma's stem-cell problem.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Allografts; Autografts; Azetidines; B-Lymphocytes; Cel | 2018 |
Ibrutinib in Refractory Classic Hodgkin's Lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Female; Hodgkin Disease; Humans; Immunosuppress | 2015 |
Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Topics: Adenine; Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Cyt | 2009 |